Foot-and-mouth disease virus structural protein VP1 elicits neutralizing and protective antibody and is probably the viral attachment protein which interacts with cellular receptor sites on cultured cells. To study the relationships between epitopes on the molecule related to neutralization and cell attachment, we tested monoclonal antibodies prepared against type A12 virus, isolated A12 VP1, and a CNBr-generated A12 VP1 fragment for neutralization and effect on viral absorption. The antibodies selected for analysis neutralized viral infectivity with varying efficiencies. One group of antibodies caused a high degree of viral aggregation and inhibited the adsorption of virus to cells by 50 to 70%. A second group of antibodies caused little or no viral aggregation but inhibited the adsorption of virus to cells by 80 to 90%. One antibody, which is specific for the intact virion, caused little viral aggregation and had no effect on the binding of virus to specific cellular receptor sites. Thus, at least three antigenic areas on the surface of foot-and-mouth disease virus which were involved in neutralization were demonstrated. One of the antigenic sites appears to have been responsible for interaction with the cellular receptor sites on the surface of susceptible cells.
The neutralization of virus by antibody is a complex phenomenon which can occur via a number of different mechanisms (38, 39) . In the case of picornaviruses, the introduction of monoclonal antibody technology has helped elucidate the mechanisms of viral neutralization (12, (19) (20) (21) 32) , characterize the epitopes involved in neutralization (22, (41) (42) (43) , locate those epitopes on various morphogenic structures (11, 13, 19, 23, 31, 40, 50) , and type picornavirus strains (16, 18, 30, 43) .
Foot-and-mouth disease virus (FMDV) is an aphthovirus in the Picornaviridae family. The viral capsid consists of 60 copies each of four proteins designated VP,, VP2, VP3, and VP4 (1) . The surface location and exposure of VP1 on intact FMDV has been determined by protease sensitivity and iodination of intact virus (10, 45, 48) .
Although the exact three-dimensional arrangement of VP1 on the virion surface is not known, purified VP1 from FMDV type A is able to elicit neutralizing antibodies and protect animals from virus challenge (2, 3, 34) . In addition, the fragments derived from CNBr treatment of isolated VP1, which generates a 13-kilodalton (kd) fragment (residues 55 to 179), or limited trypsin digestion of intact virus, which generates a 16-kd fragment of VP, (residues 1 to 144) (45) , are also immunogenic and induce protective immunity (3, 4, 33) . Trypsin treatment of purified type A or 0 virus, however, results in a loss of both infectivity and the ability of the virus to interact with its cellular receptor site (CRS) on intact cells (1, 7, 10, 14) . These data indicate that VP, acts both as the carrier of major antigenic determinants of FMDV and as the viral attachment protein which reacts with the CRS (14) .
That trypsin-treated type A virus could still induce neutralizing antibodies and protective immunity yet could no buffer. Final antibody dilutions are given in the figure legends. The virus-antibody mixture was incubated for 2 h at room temperature. Binding assays were performed on BK cells as previously described (9) with some modifications. To 100 ulI of cells at 5 x 107 cells per ml, in 1.5-ml conical tubes, 5 ,ul of virus-antibody mixture was added (multiplicity of infection, 800 particles per cell) and allowed to incubate at 4°C. At various times, tubes were removed, and the cells were washed with PBS followed by pelleting in a microfuge (Eppendorf) for 3 s. Cell-associated radioactivity was determined by trichloroacetic acid (TCA) precipitation as previously described (9).
Isotope. [5,6-3H] Calculated by computer and use of the logit-log transformation (49) . Calculated by the same computer program used to calculate endpoint, and is obtained by plotting plaque number versus antibody dilution. In addition, the antibodies could reduce the plaque titer of the radioactive seed used in all of the subsequent assays (Table 3) . Antibodies 2PD11 and 2FF11 both reduced the titer by >95%. Antibodies 7SF3, 6HE4, and 6HC4 reduced 16 , , Oe0~.
the titer from 70 to 75%, whereas 6EE2 reduced the titer by only 40%. The latter antibody also had the lowest plaque reduction neutralization titer. With all the antibodies, the reduction in plaque titer was not as dramatic as that of the titers in the plaque reduction assay. This could probably be attributed to the very high particle/PFU ratios in FMDV seeds (47) . In the labeled seed used in this study, this ratio was 4.28 x 103. This seed was diluted to the same level as was used in all subsequent experiments. Therefore, the initial particle titer which was reacted with antibody was ca.
7.7 x 10" particles per ml. In addition, the virus that contained radioactive label probably did not represent a large proportion of the total population. Thus, at the dilutions used, there was a large amount of virus that was not labeled and that also may not have been infectious but could still react with antibody. Effect of monoclonal antibodies on viral particle integrity. Recent studies have indicated that some antipoliovirus monoclonal antibodies cause aggregation of viral particles (12, 32) , and, in one case, aggregation has been implicated as the direct cause of viral neutralization (12) . FMDV-antibody complexes were analyzed by velocity sucrose gradient sedimentation, and the results (Fig. 1) indicate that the antibodies can again be divided into two general classes. Antibodies 7SF3 ( Fig. la and 40 ,000 rpm for 40 Fig. lj and k) . Thus, at neutralizing concentrations, antibodies 7SF3, 6HE4, 6HC4, and 2FF11 caused viral aggregation, whereas antibodies 2PD11, 6EE2, 6HC4, and 6FF5 caused little or no aggregation (Fig. 1) . The classification of antibodies by their effects on virion sedimentation rate is identical to their classification by doseresponse curve slopes as seen in the previous section. The antibodies were used at two different dilutions in these experiments, but there was little dose effect observed, indicating that the antibody was probably in excess. The final dilution of the virus was at 1:270. This dilution was chosen so that, in the cell adsorption experiments, the multiplicity of added virus would be ca. 800 particles per cell (see below). The same seed of labeled virus was used throughout this study. At these dilutions, however, with the exception of 6FF5, all of the labeled virus reacted with antibody since all of the counts could be bound to protein Acontaining Staphylococcus aureus (Table 4) . Thus, the lack of aggregation by 6HC4, 6EE2, 2PD11, and 6FF5 was not due to virus which had not reacted with antibody. Furthermore, when the virus peaks from these gradients were incubated with protein A-containing S. aureus, the majority of the counts were bound to the bacteria, indicating that antibody was not removed during sedimentation (data not shown).
Effect of monoclonal antibodies on the adsorption of A12 virus to cellular receptor sites. To determine whether any of the monoclonal antibodies interfered with the interaction of FMDV and the BK cell CRS, we performed binding studies with virus-antibody complexes. The results obtained with the antibodies which caused viral aggregation are shown in Fig. 2 . In each case, the results were similar. The antibodies inhibited adsorption of virus to BK cells by 50 to 70%. These results can be contrasted to those presented in Fig. 3 , in which identical experiments were done with the antibodies which did not cause viral aggregation. Two of the antibodies, 6HC4 (Fig. 3a) and 6EE2 (Fig. 3b) , caused almost total inhibition of viral adsorption. Antibody 2PD11, however, was unable to inhibit viral binding to BK cells (Fig. 3c) (20) . Similar results were obtained with 2FF11 and 6HE4 although less enhancement was seen in these two cases (data not shown). Virus reacted with antibody 2PD11 was able to bind to specific CRS on BK cells (Fig. 4b) . The binding of the virusantibody complex was inhibited >50% by unlabeled A12 virus. The small amount of virus which is aggregated by this antibody (Fig. lj and k) probably is the reason that the inhibition of binding by unlabeled virus is not as large as that in the control. A similar result was obtained for antibody 6FF5 (data not shown).
Thus, antibody-induced viral aggregation results in the failure of virus either to bind to cells or to bind to nonreceptor sites on the cell surface, whereas neutralization by 2PD11 and 6FF5 seems to occur at some event subsequent to adsorption.
DISCUSSION
The results presented in this report indicate that there are at least three antigenic domains on the surface of A12 FMDV that are involved in viral neutralization. Two of these domains are present on isolated VP1 and 12S protein subunits, and one is a conformation-specific site only found on intact virus. The mechanisms of viral neutralization which occur when the monoclonal antibodies react with these domains appear to be different. At neutralizing concentrations, one group of monoclonal antibodies caused extensive viral aggregation, and another group inhibited viral adsorption to BK cells, but one antibody (2PD11) neither aggregated virus nor prevented viral adsorption.
Recent reports suggest that there may be as many as seven poliovirus-neutralizing epitopes (20) . At least one of these epitopes might be responsible for reaction with the polio CRS on HeLa cells. In addition, neutralizing poliovirus epitopes have been found on isolated VP1 (11, 50) .
Antibody 2PD11, which defines the conformation-specific epitope found only on the intact virus, appears to neutralize at some point subsequent to viral adsorption. At an antibody concentration which reduced infectivity by 95%, only minor viral aggregation was noted, and virus-antibody complexes bound to specific receptor sites on BK cells. Mandel (35, 36) had shown previously that polyclonal poliovirus neutralizing antibody inhibits uncoating rather than penetration or attachment and suggested that neutralizing antibody stabilizes the virus in one of two conformational states defined by isoelectric point (37) . Recently, Emini et al. (20) reported that six neutralizing monoclonal antibodies, although failing to inhibit viral attachment, alter the isoelectric point of the virion. At least three of these antibodies require bivalent attachment of antibody to virus (21) . In contrast, Icenogle et al. (32) reported that a single monoclonal antibody neutralizes virus by cross-linking viral pentamers resulting in an inhibition of uncoating, without changing the electrophoretic profile of the virion. It is possible that 2PD11 may neutralize by one of these two mechanisms.
The epitope which reacts with 2PD11 is not present on 12S protein subunits (Timpone, M.S. thesis, 1982) nor on VP1 (M. J. Grubman, personal communication) and appears to be similar to a number of neutralizing monoclonal antibodies recently described for 01 FMDV (41) . In contrast with the 01 monoclonals, however, 2PD11 did not react with trypsinized virus (unpublished observations). This difference, however, might be related to serotype. Although these authors did not study the binding of virus-antibody complexes to cells, they suggested that this epitope is not identical with the cell attachment site on VP1.
Two of the antibodies which neutralize viral infectivity (6HC4 and 6EE2) seem to react with the A12 cell attachment site on VP1. Epitope mapping of this site on VP1 places it between amino acid residues 169 and 179 (Robertson et al., submitted for publication). The assignment of the cell attachment site to this region of VP, seems to satisfy some previous observations on FMDV-cell interactions.
Trypsin cleavage of VP1 on different serotypes or subtypes of intact FMDV results in peptides which have different molecular weights and is probably related to the presence or absence of arginine or lysine residues within the major antigenic variable region (residues 134 to 158). Trypsin treatment of 01 results in a large fragment (residues 1 to 138) and a smaller fragment (residues 155 to 213) which remains virion associated (8, 28, 48) . Such treatment of 01 virions did not affect the ability of the virus to induce neutralizing antibody in rabbits, although it did so at a lower level than with intact virus (29). There are conflicting conclusions regarding the effect of trypsinization on the cell attachment region of 01 virions. Barteling et al. (8) have suggested that the cell attachment site for 01 virions resides in the smaller fragment remaining after trypsinization, whereas Strohmaier et al. (48) implicated residues (amino acids 138 to 154) in the region which is not found virion associated after trypsinization. Trypsin treatment of intact A12 virus cleaves VP, at arginine 144, resulting in a 16-kd fragment (3, 45) and a smaller, uncharacterized peptide that appears to remain virion associated (unpublished observations). Such treatment results in the loss of virus cell-binding activity (10), although virions were still able to induce protective immunity in cattle (3) . Antibodies 6EE2 and 6HC4, which inhibit the binding of A12 virions to the cellular receptor, are unable to react with trypsinized virus (Robertson et al., submitted for publication), indicating that the epitope has been removed, conformationally changed, or made inaccessible to antibody.
If the small peptide remaining after trypsinization of Al2 virions is analogous to the small 01 peptide, then residues 169 to 179 should still be virion associated. If this is the case, we favor the conclusion that, upon trypsinization, the cell receptor region of A12 virions has been conformationally changed or made inaccessible to antibody.
Finally, a published comparison of nucleotide and amino acid sequence data from ten different FMDV strains representing three major serotypes detected variable amino acid residues at positions 167 to 173, which are partially located within this epitope (15) . This might explain our earlier observations that different serotypes of FMDV adsorb to host cells with different efficiencies (9, 47) .
The last functional region is defined by antibodies 7SF3, 6HE4, and 2FF11. These antibodies seem to neutralize by causing massive viral aggregation. This suggests that each antibody is binding two virions. The aggregation results in a partial inhibition of adsorption with the residual adsorption being nonspecific. These antibodies might be analogous to a monoclonal antibody which neutralized poliovirus by a similar mechanism (12) .
All of the antibodies which cause FMDV aggregation are of the same isotype (see Table 1 ). Thus, viral aggregation might be related to the isotype of the antibody. Epitope mapping studies of 7SF3 and 6HE4 on VP1 have placed the epitope between residues 145 and 168 (Robertson et al., submitted for publication). Although the 2FF11-reactive epitope has not been identified, this antibody still reacts with trypsinized virus (unpublished observations) in contrast to 7SF3 and 6HE4 (Robertson et al., submitted for publication). Since the latter two antibodies map very close to the trypsin cleavage point, their epitope might be adjacent to or partially overlapped by the 2FF11 epitope. Whether antibody-induced viral aggregation is isotype or epitope related (or both), however, it still appears to be one mechanism of viral neutralization.
Antibody 6FF5 maps in a region which may overlap the 7SF3 and 6EE2 epitopes (Robertson et al., submitted for publication) and also causes a partial inhibition of virus binding without causing viral aggregation. The residual binding with this antibody, however, is specific.
Of the seven antibodies described, all but one react with both 140S intact virus and 12S protein subunits. One of these cross-reactive antibodies (2FF11) was obtained from mice immunized with intact virus. Both virus-specific and 12S-cross-reactive monoclonal antibodies against 01 FMDV have been described (40) as well as monoclonal antibodies reactive with various poliovirus morphogenic structures (19, 31) .
Polyclonal antiserum from animals vaccinated with inactivated FMDV can be fractionated into 140S-specific and 140S-or 12S-cross-reactive components (26) . Further work indicated that the cross-reactive antibodies might be sensitizing antibodies that needed antiglobulin for neutralization and that virus reacted with this antibody could bind to a proper receptor site (27) . Our results with the cross-reacting monoclonal antibody generated with intact virus (2FF11) indicate that this antibody can neutralize directly without antiglobulin and that the virus-antibody complexes cannot bind to proper receptor sites. It is possible, however, that antibody 2FF11 might not have the properties of the polyclonal antibodies used in the previous study (27) .
This study constitutes a comparison of a number of different neutralizing anti-FMDV monoclonal antibodies, and we have attempted to show that the mechanisms of viral neutralization which occur when antibodies of different epitope specificities react with virus are not the same. In this report, we did not measure the antibody-to-virion ratios at VOL. 51, 1984 on July 4, 2017 by guest http://jvi.asm.org/ Downloaded from which these events occur. However, we have compared antibodies with approximately the same neutralizing titers and have been able to show differences in the amount of viral aggregation caused by antibody and the effect of antibody on early virus-cell interactions. Antibody 2PD11 had ca. 100-fold-greater plaque reduction-neutralization titer than did most of the other antibodies, yet it caused little viral aggregation and did not interfere with viral adsorption. It has been shown that, for a single antipoliovirus monoclonal antibody, the virion/antibody ratio can affect the extent of viral aggregation (32) . It should also be pointed out that different antibodies which react with the same epitopes (i.e., 6EE2 and 6HC4 or 7SF3 and 6HE4) or with epitopes which are closely located (i.e., 2FF11 and 7SF3) all exhibit the same effects on viral aggregation.
In addition, antibody 6EE2 had a 300-fold-lower plaque reduction-neutralization titer than did antibody 6HC4 (Table  2 ), yet at a 1:5 dilution, 6EE2 inhibited the adsorption of labeled virus to BK cells as well as did 6HC4 at a 1:50 dilution ( Fig. 3a and b) .
All of the antibodies used in this study were capable of neutralizing in vivo in a mouse protection test (Morgan et al., manuscript in preparation). In addition, one of the antibodies (7SF3), when presented in high concentration, passively protected a pig from FMDV challenge (D. 0. Morgan, Conf. Res. Work. Anim. Dis. 1983, p. 211). Thus, the mechanisms of viral neutralization in vitro probably are also operative in vivo and knowledge of the epitopes involved will help determine which types of epitopes would be most advantageous to have in viral vaccines.
